Scott Minick

Scott Minick is a biopharma executive and venture capital investor who currently serves as a Board Member at BPGbio and Executive Chairman at Aira Tech Corp. Previously, he was a Managing Director and Venture Partner at ARCH Venture Partners, where he executed over 50 investment deals in the life sciences sector. As the President and Chief Operating Officer of SEQUUS Pharmaceuticals, he led the 1995 FDA approval and commercial launch of Doxil before the company was acquired by ALZA for $580 million. He also served as the Chief Executive Officer of BIND Therapeutics, guiding the nanotechnology-focused oncology firm through its initial public offering in 2013. Minick holds additional board positions at Goldilocks Therapeutics and the California Pacific Medical Center. His career centers on guiding early-stage biotechnology startups through clinical drug development, regulatory approvals, and strategic acquisitions.